Occam Places Wendy Young as Executive Partner at MPM Capital

Wendy Young joins MPM Capital as Executive Partner, having spent 25 years in biopharma, and most recently 15 years at Genentech, where she led small-molecule drug discovery. At MPM, she will use her years of chemistry and drug discovery experience to advise on investments and support creation of new company ventures.

Occam Places Jim Wang as SVP, Regulatory Affairs at Adverum

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, has appointed Jim Wang, Ph.D., senior vice president, head of regulatory affairs. Reporting directly to Laurent Fischer, M.D., Adverum’s president and chief executive officer, Dr. Wang will lead regulatory strategies and execution for the company’s product pipeline.

Dr. Wang joins Adverum from PTC Therapeutics, where he served as vice president, global head of regulatory strategy, leading the planning and execution of worldwide regulatory activities across all therapeutic areas focusing on rare disease. He also provided oversight to a cross-functional team for the marketing application of the gene therapy product eladocagene exuparvovec. Previously, he worked with Spark Therapeutics, serving as vice president, head of regulatory affairs strategy.

Dr. Wang earned his Ph.D. in chemistry from the University of Illinois at Urbana-Champaign and an MBA from Pennsylvania State University.

Occam Places Sapna Srivastava on the Board of Nuvalent

Dr. Srivastava has over 20 years of experience as a senior executive in the biopharmaceutical industry. She has served as the Chief Financial Officer at eGenesis Bio since April 2021. From September 2017 to January 2019, Dr. Srivastava served as the Chief Financial and Strategy Officer at Abide Therapeutics, Inc., a biopharmaceutical company that was acquired by H. Lundbeck A/S in 2019. From April 2015 to December 2016, Dr. Srivastava served as the Chief Financial and Strategy Officer at Intellia Therapeutics, Inc. (NASDAQ: NTLA), a gene editing company. Previously, for nearly 15 years Dr. Srivastava was a senior biotechnology analyst at Goldman Sachs, Morgan Stanley, and ThinkEquity Partners, LLC.

Occam Places Mike Sherman on Board of Werewolf Therapeutics

Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, has added Mike Sherman, Chief Executive Officer of Chimerix, Inc., as a member of its Board of Directors.

Mike Sherman joins the Werewolf Board of Directors with more than 30 years’ experience in the biotechnology and medical technology industries. Before joining Chimerix, he served as Chief Executive Officer of Endocyte, Inc. and led it to its $2.1 billion acquisition by Novartis in 2018. Mr. Sherman joined Endocyte in 2006 and served as its Chief Financial Officer and Chief Operating Officer prior to becoming Chief Executive Officer in 2016. He repositioned the company by re-prioritizing the pipeline, acquiring an external asset, and aggressively executing a phase 3 regulatory and clinical strategy, and was instrumental in Endocyte’s IPO and four subsequent financings. Prior to joining Endocyte, he served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, which was acquired by Boston Scientific Corporation. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth

Occam Places Chulani Karunatilake as CTO at Werewolf Therapeutics

Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Chulani Karunatilake, Ph.D. as Chief Technology Officer (CTO). Dr. Karunatilake brings more than 30 years of experience in Chemistry and Manufacturing Controls (CMC) process and strategy development and will oversee manufacturing operations in the newly formed role

Chris Gibson

CEO | Recursion Pharmaceuticals

"Occam has been a formidable recruiting partner for Recursion. Over the past three years, they have helped us make key additions to the senior executive team and Board. The firm has consistently provided a unique blend of nuanced and ethical judgement, tireless and creative effort, and strategic insight in helping us develop a holistic organizational plan as Recursion has evolved."
Find out more Read the Case Study

Julie Sunderland

Managing Director | Biomatics Capital

"Bill Holodnak’s deep understanding of humanity allows him to match people and opportunities in a magical, almost musical way. In other words, it’s jazz baby."
Find out more

Josh Wolfe

Co-Founder & Managing Partner | Lux Capital

"Occam has been a great and valued recruiting partner for Lux. They impress with business moxie, psychological acuity, ruthless objectivity and speed. A team and search firm apart."
Find out more

Bob More

Managing Director | Alta Partners

"Occam brings an uncommon mix of intelligence, discipline and instinct to executive recruiting. Building companies is more art than science; they bring both to the party. In enduring fashion, Occam has mastered the human side of venture capital."
Find out more

Frederic Kerrest

Executive Vice Chairperson, COO & Co-Founder | Okta

“Thorough, tireless, and professional, and they listen. Occam is a search firm that matches the entrepreneurial intensity of its clients. Results delivered with intelligence, urgency and style.”
Find out more

Recent Placements

Occam Places Wendy Young as Executive Partner at MPM Capital

Find out more

Occam Places Jim Wang as SVP, Regulatory Affairs at Adverum

Find out more

Occam Places Sapna Srivastava on the Board of Nuvalent

Find out more

Occam Places Mike Sherman on Board of Werewolf Therapeutics

Find out more

Occam Places Chulani Karunatilake as CTO at Werewolf Therapeutics

Find out more

Why Occam?

Occam Global is a strategic human capital advisory firm dedicated to rigorous objectivity and enlightened aggression in executive recruiting and organizational development.

Our mission is to work selectively with exceptional clients for the long term. If candor and completeness is your preference in matters of Human Capital, the most opaque of asset classes, Occam is the partner for you.

The medieval philosopher William of Occam is the firm’s adopted patron saint. William spoke plainly and thought with rigor and humanity. These qualities yielded elevated ideas and also got him into a few punch-ups with the Holy See. His enduring concept, Occam’s Razor—“Lex Parsimoniae”—embodies an unrelenting focus on essentials in problem solving. His and our solutions strive for elegant simplicity.

  • Rich expertise and global contacts in technology, healthcare, financial services, and entrepreneurial organizations
  • Objective yet unconventional approach to problem solving
  • Virtually no off-limits constraints
  • Milestone-driven fee structure
Meet our executive headhunters

Services

Occam’s commitment is to provide an abundance of precisely qualified candidates through an open inquiry; due diligence for selection; and guidance on closure and integration. Our approach is relationship rather than transaction-driven.

Executive Search

Find out more
+
Executive
Placements
+
Board
Placements

Board of Directors Search

Find out more

Human Venture Capital

Find out more

Industries

Occam works with a wide range of high-growth industries as a trusted partner in executive recruitment.

  • Biotechnology
  • Pharmaceuticals
  • Life Sciences
  • Medical Devices
  • Healthcare
  • Technology
  • FinTech
  • Sustainable Energy
  • Venture Capital
  • Private Equity

Select Clients

  • Recursion Pharamceuticals
  • Elicio Therapeutics
  • PACT Pharma
  • Pacira Biosciences Inc.
  • Tmunity
  • CytomX Therapeutics
  • Generation Bio
  • Beam Therapeutics
  • Variant Bio
  • Semma Therapeutics
  • eGenesis Engineering
  • Oncorus
Previous Slide Next Slide

News & Views

Industry insights, client successes, and a deeper dive into the world of executive search and C-suite recruiting.

View all news

Occam Places Wendy Young as Executive Partner at MPM Capital

Read Story

Occam Places Jim Wang as SVP, Regulatory Affairs at Adverum

Read Story

Occam Places Sapna Srivastava on the Board of Nuvalent

Read Story

Occam Places Mike Sherman on Board of Werewolf Therapeutics

Read Story

Occam Places Chulani Karunatilake as CTO at Werewolf Therapeutics

Read Story

Occam Places Jeff Landau as CBO and Chau Cheng as VP IR at CytomX Therapeutics

Read Story

Contact

80 Broad St, STE 2801
New York, NY, 10004
United States

    I am interested in*